Measurements have been made of the tissue content of phosphoribosyl pyrophosphate (PPRibP) and of a range of metabolic intermediates involved in the energy charge of the cell, the glycolytic and pentose phosphate pathways, and of the activity of the enzymes of the pentose phosphate pathway and of PPRibP synthetase (EC 2.7.6.1) in the livers of normal, diabetic, insulin-treated diabetic and starved rats and in livers of rats previously starved and then re-fed with high-fat or high-carbohydrate diets. Diabetes, starvation and high-fat diet all caused a fall in the hepatic PPRibP content, whereas insulin treatment and high-carbohydrate diet raised the tissue content. A positive correlation was shown between the PPRibP content and ATP, energy charge and the cytosolic [NAD+]/[NADH] quotient. A positive association between the PPRibP content and the flux of glucose through the pentose phosphate pathway and the synthesis of ribose 5-phosphate via the oxidative enzymes of that pathway, including ribose-5-phosphate isomerase (EC 5.3.1.6), was also observed. A negative correlation was found between the ADP, AMP and Pi contents, and no correlation existed between PPRibP content and the enzymes of the non-oxidative branch of the pentose phosphate pathway. There was no correlation between hepatic PPRibP content and the activity of PPRibP synthetase measured in vitro. These results are considered in relation to the control of PPRibP synthetase in the liver in vivo.
INTRODUCTION
Phosphoribosyl pyrophosphate (PPRibP) is a primary substrate in nucleotide synthesis by both the 'de novo' and the salvage pathways, and is itself an activator of amidophosphoribosyltransferase (EC 2.4.2.14) , the first enzyme of the 'de novo' pathway of synthesis (Becker et al., 1979; Pilz et al., 1984) , and ofcarbamoyl-phosphate synthetase (glutamine) (EC 6.3.5.5) , the isoenzyme involved in pyrimidine synthesis (Tatibana et al., 1982) .
PPRibP is made solely by PPRibP synthetase (EC 2.7.6.1), an enzyme which is subject to a complex system of control. It is dependent on ribose 5-phosphate availability, cell energy levels and end-product inhibition, and both Pi and bivalent cations are absolute requirements for activity, Pi having a stimulatory effect over a broad range of concentrations (Fox & Kelley, 1971; Becker et al., 1979; Raivio et al., 1981) . Of the substrates for PPRibP synthetase, Atkinson & Fall (1967) have drawn attention to the role of the 'energy charge' in the regulation of the enzyme. There is also evidence, albeit controversial, that the availability of ribose 5-phosphate is also a crucial factor in regulating the tissue PPRibP content. In fibroblasts (Raivio et al., 1981) , cultured liver cells (Bashkin & Sperling, 1978) and liver slices (Boer et al., 1976) , ribose 5-phosphate does not appear to be limiting for PPRibP formation, except when PPRibP synthetase is activated by high concentrations of Pi, this conclusion being largely based on the failure of Methylene Blue to allow increased PPRibP synthesis despite measured increases in the flux through the oxidative pentose phosphate pathway. On the other hand, Buchanan et al. (1982) have shown that when the pentose phosphate pathway is accelerated by the inclusion in the incubation media of hydrogen acceptors which do not, simultaneously, compromise the production of ATP, then the rate of formation of ribose 5-phosphate is limiting for the production of PPRibP in 3T6 fibroblasts. Further, Pilz et al. (1984) have shown that there is a parallel increase in PPRibP and cellular ribose 5-phosphate concentrations when cell cultures are exposed to increasing glucospwncentrations. In addition, a significant corration as been shown to exist between the enzymes of the pentose phosphate pathway (Steer et al., 1985) , the flux of glucose through the oxidative pentose phosphate pathway (Steer et al., 1982 (Steer et al., , 1985 and accelerated growth in the early renal hypertrophy of diabetes. Thus, although considerable evidence exists, largely based on experiments involving Methylene Blue, which suggests that the oxidative branch of the pentose phosphate pathway is only minimally involved in the regulation of PPRibP availability, other evidence, based on less controversial hydrogen acceptors [amino acid synthesis, ascorbic acid synthesis (Buchanan et al., 1982) or phenazine methosulphate (Steer et al., 1982) ] suggests that the supply of ribose 5-phosphate via the two dehydrogenases of the pentose phosphate pathway is crucial.
Two previous studies concerned with the regulation of growth (Kunjara et al., 1986a,b,c) . Thus diabetes produces opposite effects in mammary gland and kidney. In the mammary gland there is a diminution of the rates of milk production and protein synthesis, and of RNA content, and the PPRibP concentration falls (Kunjara et al., 1986b) . In the kidney, on the other hand, diabetes results in an initial hypertrophy, with an increased rate of protein and nucleic acid accretion, but, despite this contrast, the PPRibP concentration behaves in a similar fashion in the two tissues in that there is a fall in both cases (Kunjara et al., 1986a,b) . This apparent paradox of wasting in the mammary gland on the one hand, and accelerated growth processes in the kidney on the other, both being associated with a fall in tissue concentration of PPRibP in diabetes led to the present investigation of the hepatic response to diabetes. The effects of diabetes, insulin, high-and lowcarbohydrate diets and starvation on the hepatic concentration of PPRibP and on PPRibP synthetase have been measured. There is a substantial background of knowledge of the changes occurring in the alternative pathways of glucose metabolism, the redox state of the cell compartments, the energy charge of the cell and the metabolite profile under these conditions (Krebs & Veech, 1969; Greenbaum et al., 1971; Casazza & Veech, 1986a) , against which to examine the alterations in PPRibP concentration in order to gain further insight into factors, in particular the role of insulin, in the regulation of this key precursor of nucleotide synthesis.
METHODS Animals
The rats used were of the Wistar strain weighing, at the outset of the experiment, 200-220 g.
Experimental treatments
Induction of diabetes. Experimental diabetes was induced by the intravenous injection of streptozotocin (60 mg/kg body wt.). Insulin, when appropriate, was given subcutaneously as either 2 or 5 i.u. (Monotard; Novo) daily for 3 days.
Dietary regimes. The composition of the diets given and the mode of administration of the diets were as described by Greenbaum et al. (1971) . Starved rats were allowed free access to water.
The animals were killed by cervical dislocation at the times stated in the Tables.  Analytical procedures Measurement of the tissue content of metabolic intermediates. Except for PPRibP, these measurements were made on HCl4 extracts of freeze-clamped livers by standard procedures as described in Bergmeyer (1974) and in Greenbaum et al. (1971) . The extraction and measurement of PPRibP were as previously described (Kunjara et al., 1986a) . Xylulose 5-phosphate was measured by the method of Racker, as described in Bergmeyer (1974) .
Measurement of the activity of the enzymes of the pentose phosphate pati;way. The activities of glucose-6-phosphate dehydrogenase (EC 1.1.1.49), 6-phosphogluconate dehydrogenase (EC 1.1.1.44), ribose-5-phosphate isomerase (EC 5.3.1.6), ribulosephosphate 3-epimerase (EC 5.1.3.1), transketolase (EC 2.2.1.1) and transaldolase (EC 2.2.1.2) were measured in the high-speed supernatant of a 1:10 (w/v) liver suspension in 0.25 M-sucrose medium buffered with 0.02 M-triethanolamine, pH 7.4, and containing 0.12 mmdithiothreitol, by the methods described by Novello & McLean (1968) .
RESULTS

Effect of diabetes, insulin and diet on hepatic PPRibP concentration and PPRibP synthetase activity
The hepatic concentration of PPRibP was significantly decreased in diabetes and in states with a depressed intake of carbohydrate, i.e. starvation for 3 days or starvation followed by re-feeding with a high-fat diet. In diabetes, the fall in PPRibP concentration was most marked in the 20-day-diabetic group (-31 00); there was evidence that this effect was progressive with duration of diabetes, as shown by the smaller (-170%) decrease in PPRibP concentration seen 5 days after treatment with streptozotocin ( Table 1 ). The activity of PPRibP synthetase showed only minor changes, and in the 20-day-diabetic rat was only 90% less than the control value (Table 1) . After starvation for 3 days, the declines in PPRibP and PPRibP synthetase were approximately parallel; however the administration of a high-fat diet to starved rats produced the most pronounced fall in PPRibP concentration (-38%) seen in these present experiments. There was no parallel fall in PPRibP synthetase (Table 1) .
The effect of starvation followed by re-feeding with a high-carbohydrate diet was to cause a massive overshoot in the hepatic concentration of PPRibP (+60%). This overshoot in PPRibP concentration was not accompanied by any increase in PPRibP synthetase activity; indeed, there was a small, but significant (-14%), decrease in activity per g of liver. Diabetic rats treated for 3 days with a low dose of insulin (2 i.u./day) showed little restoration of PPRibP or PPRibP synthetase activity (Table 1) . As shown in Table 1 , this dose of insulin was insufficient to restore normoglycaemia over a 24 h period. A higher dose of insulin (5 i.u./day) restored normoglycaemia and the PPRibP content of the liver. There was no correlation between the activity of PPRibP synthetase activity per g of liver and the PPRibP concentration. Table 1 also shows the changes in total liver weight and total hepatic RNA. There is a severe loss of RNA from liver in starved rats and in the starved group re-fed with the high-fat diet; there is a substantial restoration of RNA synthesis in the group re-fed with the highcarbohydrate diet. Treatment of diabetic rats with high doses of insulin also led to a significant elevation of the hepatic RNA content (Table 1) .
Correlation between hepatic PPRibP and energy status of the cell
The results shown in Fig. 1 illustrate that a positive correlation exists between the hepatic concentration of ATP, the energy charge of the cell and the PPRibP concentration (r = 0.95 and 0.94 respectively). These results are in accord with those of Atkinson & Fall (1967) on the properties of PPRibP synthetase isolated from Escherichia coli. (Krebs & Veech, 1969; Casazza & Veech, 1986b) .
Also shown in Fig. 1 Conversely, the data in Fig. 2 illustrates the negative correlation found between the hepatic PPRibP concentration and the ADP and AMP concentrations (r = -0.97 and -0.96 respectively), again in accord with Atkinson & Fall (1967 Casazza & Veech (1986b) , was linearly correlated with the hepatic PPRibP concentration (r = 0.98) (Fig. 1) . A positive correlation was also found between the hepatic concentration of PPRibP and the flux of glucose through the pentose phosphate pathway, the 6-phosphogluconate and xylulose 5-phosphate concentrations. However, the relationship between PPRibP concentration and the above parameters was logarithmic rather than linear (see Fig. 3b ). As for the enzymes involved in the oxidative route to ribose 5-phosphate formation, there was evidence for a positive association between the activity of glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and ribose-5-phosphate isomerase with the hepatic concentration of PPRibP (Table 2) . On the other hand, no association was found between the activities of the non-oxidative route to pentose phosphate formation, namely transketolase, transaldolase and pentose phosphate epimerase, and PPRibP concentration in the livers of these groups of rats (Table 2) .
DISCUSSION
The present experiments do not permit a direct evaluation of the contribution of the relative rates of PPRibP synthesis and degradation to the steady-state concentration. However, an increased biosynthesis and bioavailability, and more rapid utilization, of PPRibP for nucleotide synthesis is indicated by the increases, greater than in the corresponding control rats, in the total hepatic RNA over the experimental period in the high-insulin and high-carbohydrate states. In each of these groups, the direction of change of the steady-state PPRibP concentration paralleled the change in requirement for nucleotides for RNA synthesis. Thus in the following discussion the assumption is made that, in the present conditions, in the liver a rise in the measured concentration of PPRibP equates with an increase in the synthesis of this compound.
In the present experiments there is evidence for an increase in the supply of the required substrates, ribose 5-phosphate via the pentose phosphate pathway and ATP via glycolytic flux, both of which appear to play a regulatory role in the control of PPRibP synthesis; the apparently lesser role played by Pi is also considered. Energy charge and Pi
The high positive correlation between the PPRibP concentration and ATP and the [NAD+]/ [NADH] quotient [a parameter reflecting the rate of glycolysis and ATP production (Krebs & Veech, 1969; Veech et al., 1970; Greenbaum et al., 1971 )] (Fig. 1) and the negative correlation with respect to ADP and AMP (Fig. 2) implies a significant regulatory role for the energy charge on PPRibP synthesis and is consistent with the known inhibitory action of ADP on PPRibP synthetase (Atkinson & Fall, 1967; Becker et al., 1979 ).
An unexpected aspect of the present work, in view of the many observations stressing the importance of Pi as an activator of PPRibP synthetase (see Hershko et al., 1969; Fox & Kelley, 1971; Planet & Fox, 1976; Bashkin & Sperling, 1978; Becker et al., 1979; Raivio et al., 1981) , was the apparent lack of a positive correlation between the liver concentrations of Pi and PPRibP. Previous reports show that, although comparatively large changes in extracellular Pi (25-60 mM) are required to increase the activity of PPRibP synthetase in intact cells (Bashkin & Sperling, 1978) , much smaller variations in the Pi content of the medium (1-5 mM) dramatically change the activity of the enzyme when purified preparations of the enzyme are used and no cell barriers have to be circumvented. This discrepancy between the extracellular and intracellular Pi concentrations can largely be explained in terms of the high gradient across the cell membrane for this ion. Planet & Fox (1976) have shown that exposing erythrocytes to an external medium containing 0, 10 mm or 20 mM-Pi resulted in intracellular values of0.5, 1.5 and 2.4 mm. These latter concentrations are well within the range which Planet & Fox (1976) found as being capable of producing substantial increases in cellular PPRibP.
The total Pi per g of liver found in the present study is of the order of 2.7-4.1 mm, i.e. within the range where it might be expected that the higher concentrations of intracellular Pi would be associated with the higher concentrations of PPRibP. In the present work, the reverse appears to be true, with a negative correlation existing between the Pi and PPRibP contents, and this would suggest that alternative forms of regulation must be considered. One conclusion to be drawn from the present data on freeze-clamped liver preparations from rats under different short-term hormonal or dietary conditions is that ATP and the energy charge of the cell have an over-riding regulatory effect on hepatic PPRibP concentration. This does not preclude effects of Pi in particular cell compartments, or an indirect action of Pi, e.g. as manifest through regulation of glycolytic flux, and thus of ATP concentrations, in the cytosol, although the apparent negative correlation between hepatic PPRibP concentration and Pi concentrations makes it unlikely that P1 is the dominant regulator of hepatic PPRibP in vivo. The Km for ATP for purified human erythrocyte PPRibP synthetase has been reported as 14 gM (Fox & Vol. 244 and the flux through the oxidative pentose phosphate pathway (PPP), plotted on a log scale. Ribose 5-P was calculated from the tissue content of xylulose 5-P by using the equilibrium constants of ribose-5-phosphate isomerase and ribulose-phosphate 3-epimerase as given by Casazza & Veech (1986b) . Kelley, 1971) . It seems possible that, at the high cell concentrations of ATP found in vivo (of the order of 2-3 mM), the kinetic parameters of other effector molecules on hepatic PPRibP synthetase may be modified. Supply of ribose 5-phosphate There are a number of systems in which it has been shown that, given the appropriate concentration of Pi, the rate of formation of PPRibP is related to the supply of ribose 5-phosphate via the oxidative pentose phosphate pathway. Bashkin & Sperling (1978) (Fig. 3) ; and (iii) the activities of the enzymes of the oxidative segment of the pentose phosphate pathway, including ribose-5-phosphate isomerase ( directs pentose phosphate to the non-oxidative segment of the pentose phosphate pathway and is the more active enzyme, did not, nor did the activity of transketolase or transaldolase ( Table 2 ). The importance of ribose phosphate isomerase in directing glucose metabolism in the pentose phosphate pathway towards ribose 5-phosphate formation is supported by the measurement of the hepatic enzyme profile in rats bearing the growthhormone-secreting pituitary tumour STW6, where liverweight increases were accompanied by a greater increase in this enzyme than in the other enzymes of the pentose phosphate pathway (Gumaa et al., 1969) . Calculating the hepatic ribose 5-phosphate from the measured xylulose 5-phosphate content, by using the equilibrium constants determined by Casazza & Veech (1986b) , it is found that the normal control value is approx. 8 /M, compared with 3.5 /M reported by Casazza & Veech (1986a) . The similarly calculated range of ribose 5-phosphate concentrations in the experimental groups in the present experiments is 3-50SM. Fox & Kelley (1971) reported the Km of the purified erythrocyte enzyme to be 33 /iM, so that the present values span the important physiological range.
The present results appear to indicate that PPRibP bioavailability in liver is most closely controlled by the energy charge and supply of ribose 5-phosphate via the pentose phosphate pathway, and that a lesser role is played by Pi and the absolute amount of PPRibP synthetase present.
